Phase I design
NSCLC
NSCLC
Two different schemes of administration will be investigated:
Sequential administration (scheme 1): SBRT (3 fractions of 8 Gy in 5 days) starting on week 1, followed by the first injection of atezolizumab + tiragolumab at week 2, then every 21 days.Concomitant administration (schema 2): SBRT (3 fractions of 8 Gy in 5 days) starting on week 1, with the first injection of atezolizumab + tiragolumab concomitant to the first radiotherapy fraction, then every 21 days.Immunotherapies will be administered intravenously: atezolizumab (1200 mg) first, then tiragolumab (600 mg) second. The fixed dose of 600 mg was selected on the basis of available clinical pharmacokinetics, efficacy, and safety data from the combined phase Ia/phase I study (GO30103), with single-agent tiragolumab or tiragolumab in combination with atezolizumab. This dose regimen was used in the CITYSCAPE trial that assessed the atezolizumab and tiragolumab combination in metastatic NSCLC [
Study design. Sequential schedule (top panel), concomitant schedule (bottom panel)